Jump to content

Peripherally acting μ-opioid receptor antagonist

From Wikipedia, the free encyclopedia
(Redirected from PAMORA)

Peripherally acting μ-opioid receptor antagonists (PAMORAs) are a class of chemical compounds that are used to reverse adverse effects caused by opioids interacting with receptors outside the central nervous system (CNS), mainly those located in the gastrointestinal tract. PAMORAs are designed to specifically inhibit certain opioid receptors in the gastrointestinal tract and with limited ability to cross the blood–brain barrier. Therefore, PAMORAs do not affect the analgesic effects of opioids within the central nervous system.[1]

Discovery and development

[edit]

Opioid drugs are known to cause opioid-induced constipation (OIC) by inhibiting gastric emptying and decreasing peristaltic waves leading to delayed absorption of medications and more water absorption from the feces. That can result in hard and dry stool and constipation for some patients.[2]

OIC is one of the most common adverse effects caused by opioids, so the discovery of PAMORAs can prevent the effects that often compromise pain management.[3]

Methylnaltrexone bromide was the first medication in the drug class approved by the FDA.[4] It was discovered in 1979 by Leon Goldberg, a pharmacologist at the University of Chicago. Having witnessed the suffering of a dying friend with OIC, Goldberg tested various derivatives of naltrexone, a drug known to block the effects of opioids. His objective was to find a drug that could not pass the blood brain barrier, without affecting the analgesic effects of the opioids. After Goldberg died, his colleagues at the university continued to develop the compound. It was approved by the FDA in April 2008, originally for OIC in adult patients with advanced illness and later in adult patients with chronic noncancer pain.[5]

In the late 1970s, Dennis M. Zimmerman and his co-workers from Lilly Research Laboratories, Indiana, did research on structural concepts for narcotic antagonists defined in a 4-phenylpiperidine series.[6] They reported N-methyl-trans-3,4-dimethyl-4-phenylpiperidine to be pure opioid receptor antagonist with a new pharmacophore. To increase the potency they attached a phenolic group to the aromatic ring, N-methyl-trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine. That structure was used to design and develop other opioid receptors antagonists such as alvimopan.[5] Alvimopan was approved later in 2008 for in-hospital use to increase the gastrointestinal function following a partial large or small bowel resection with primary anastomosis. Naloxegol was approved in September 2014 and naldemedine in March 2017, both for the treatment of OIC in adult patients with chronic cancer.[7][8][9][10]

Mechanism of action

[edit]

PAMORAs act by inhibiting the binding of opioids agonist to the μ-opioid receptor (MOR). The objective of PAMORAs treatment is to restore the enteric nervous system function (ENS). The MOR is found in several places in the body and PAMORAs is a competitive antagonist for binding to the receptor. The MORs in the gastrointestinal tract are the main receptors that PAMORAs are intended to block and prevent the binding of opioid agonists.[11] PAMORAs are used in the treatment of opioid-induced bowel dysfunction (OIBD), a potential adverse effect caused by chronic opioid use. PAMORAs act on the three pathophysiological mechanisms of this adverse effect. They act on gut motility, gut secretion and sphincter function.[12]

PAMORAs effect on gut motility is that it can increase the resting tone in the circular muscle layer. The antagonist enhances the effect on tonic inhibition of the muscle tone. This will normalize the tone in the circular muscle layer and therefore prevent opioid-induced rhythmic contractions. When these two factors are combined, it results in decreased transit time. Impliedly these effects will decrease the passive absorption of fluids which helps with decreasing OIBD symptoms such as constipation, gut spasm and abdominal cramp.[13]

PAMORAs effect on gut secretion will help reverse the decreased cAMP formation that opioid agonists induce.[14] Also, the antagonist will establish a normal secretion of chloride. Opioids agonists can also reduce the secretion of peptides by increasing the sympathetic nervous system through the μ-receptors in the ENS, which can lead to drier and harder stool. PAMORAs work against it so the stool becomes softer and less dry.[13]

PAMORAs effect on the function of the sphincter is in theory to regulate the movement coordination. The antagonist can prevent sphincter of Oddi dysfunction that is caused by opioids.[15] Antagonists can also reduce opioid-induced anal sphincter dysfunction. The dysfunction is tied to straining, hemorrhoids and incomplete emptying.[16]

Structure–activity relationship

[edit]

Even though μ-opioid receptor (MOR) targeting drugs have been used for a long time, not much is known about the structure-activity relationship and the ligand-receptor interactions on the basis of well-defined biological effects on receptor activation or inhibition. Also, the distinction in the receptor-ligand interaction patterns of agonists and antagonists is not known for sure. One theory states that the morphinans biological activity could be determined by the size of the N-substituents. For example, antagonists usually have larger substituents, such as allyl- or cyclopropyl methyl at the morphinan nitrogen, while agonists generally contain a methyl group. On the other hand, agonist activity is also shown in ligands with larger groups at the morphinan nitrogen, and therefore this hypothesis is challenged.[17]

Structure

[edit]
The similarity in structural characteristics of MOR-antagonistsA = Benzene ring, B = Tetrahydrofuran, C, D = Cyclohexane rings, E = Piperidine ring

Methylnaltrexone bromide, naloxegol, and naldemedine all have similar structures, which is not far away from the chemical structure of morphine and other MOR-agonists. All contain a rigid pentacyclic structure that involves benzene ring (A), tetrahydrofuran ring (B), two cyclohexane rings (C and D) and a piperidine ring (E).[18] The most important functional groups for the biological action of opioids are the hydroxyl group on the phenol, N-methyl group, ether bridge between C4 and C5, the double bond between carbon number C7 and C8 and the hydroxyl groups at C3 and C6. The phenolic ring and its 3-hydroxyl group is vital for the analgesic effects as the removal of the OH group decrease the analgesic activity 10-fold. There is another principle for the hydroxyl group on C6 as the removal enhances its activity. The increased activity is mainly because of the increased lipophilicity and the increased ability to cross the blood–brain barrier. Naldemedine has the hydroxyl group while methylnaltrexone bromide has a ketone group and naloxegol has an ester. The double bond between C7 and C8 is not required for the analgesic effect and reduction of the double bond will increase the activity. None of the antagonists has a double bond in their structure. The N-substituent on the skeleton is thought to determine the pharmacological behavior and its interaction with MOR. It is also thought to play a key role in distinguishing antagonists from agonists. Allyl group, a methylcyclopropyl group or a methylcyclobutyl as N-substituent groups are thought to lead antagonist activity.[19][20][21]

Binding site

[edit]

Agonists and antagonists form certain chemical bonds with amino acids that construct the MOR. The majority of antagonists, as well as agonists, are predicted to form charged interaction with Asp147 and a hydrogen bond with Tyr148. However, majority of antagonists also form additional polar interactions with other amino acid residues such as Lys233, Gln124, Gln229, Asn150, Trp318 and Tyr128. Only a small minority of agonists form the same additional polar interactions. Both agonists and antagonists are known to form hydrogen bonds with His297.[22]

It can be concluded that interactions with the amino acid residues, Asp147 and Tyr148 are essential for the ligand to bind to the receptor and the molecules that form additional polar interactions with other residues are more often antagonists than agonists.[17]

The N-substituent group can form hydrophobic bonds with Tyr326 and Trp293 and the aromatic and cyclohexane rings can form similar bonds to Met151. The backside of the ligand can also form a hydrophobic bond, but with Val300 and Ile296.[22]

Methylnaltrexone bromide

[edit]

Methylnaltrexone bromide is the bromide salt form of methylnaltrexone, a quaternary methyl derivative of noroxymorphone. The methyl group and the quaternary salt formation increase the polarity and reduce the lipid solubility thereby restricts the blood–brain-barrier penetration. Methylnaltrexone has eight times higher affinity for MOR than for κ-opioid receptor (KOR) and δ-opioid receptor (DOR).[23] Naltrexone forms interaction with Asp147 and Tyr148 along with a hydrogen bond with Lys233.[24]

Different development stages of methylnaltrexone bromide. 1. Noroxymorphone 2. Naltrexone 3. Methylnaltrexone 4. Methylnaltrexone bromide

Alvimopan

[edit]
The development of alvimopan from 4-(3-hydroxyphenyl)-3,4-dimethylpiperidine

Peripherally selective trans-3,4-dimethyl-4-(3-hydroxylphenyl)piperidine opioid antagonists were developed for the treatment of gastrointestinal motility disorder by Zimmerman and his coworkers. From that, they derived the 4-(3-hydroxyphenyl)-3,4-dimethylpiperidine scaffold with functional groups spanning various sizes, charge, and polarity to reach peripheral opioid receptor antagonism while decreasing CNS drug exposure. The in vitro μ-Ki, in vivo AD50, and ED50 and peripheral index (ratio) was examined for several selective analogs, and from that, they found out that the trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, Alvimopan, gave the best results.[5] The large zwitterionic structure and the high polarity prevents Alvimopan from crossing the blood–brain barrier, potency at binding peripheral MORs is thereby 200 times that of central MORs.[25]

Naloxegol

[edit]

Naloxegol is a polyethylene glycol-modified derivative of α-naloxol. Naloxegol has a similar form as naloxone as a heteropentacyclic compound both of which have an allyl group attached to the amine of the piperidine ring. However, naloxegol has a monomethoxy-terminated n=7 oligomer of PEG connected to the 6-alpha-hydroxyl group of ɑ-naloxol via an ether linkage. The PEG moiety increases the molecular weight and therefore restricts the uptake of naloxegol into the CNS.[26] Furthermore, pegylated naloxegol becomes a substrate for the P-glycoprotein efflux transporter that transports the compound out of the CNS.[27]

Naldemedine

[edit]

Naldemedine has a similar chemical structure as naltrexone but with an additional side chain that increases the molecular weight and polar surface area of the substance. Like naloxegol, naldemedine is a substrate of the P-glycoprotein efflux transporter. These properties result in less penetration into the CNS and decrease possible inference with the effects of opioid agonists.[28] Naldemedine is a dual antagonist for MOR and DOR. Activation of the DOR has been known to cause nausea and/or vomiting, so a dual antagonist can decrease both OIC and nausea/vomiting.[29]

Pharmacokinetics

[edit]

The molecular weight, bioavailability, protein binding, elimination half-life, the time to achieve maximum plasma concentration and binding affinity are present in the table below.[26][23]

Table 1: Pharmacokinetic parameters of peripherally acting μ-opioid receptor antagonists[30][31][32]
Chemical name Chemical structure Molecular weight (g/mol) Bioavailability (%) Plasma protein binding (%) t1/2 (h) tmax Ki μ (nM) Ki κ (nM) Ki δ (nM)
Methylnaltrexone bromide
436,3 Low 11-15 8 30 min 5.50 32.1 3453.8
Alvimopan

424,53 6 80-90 10-17 2 h 0.77 40 4.4
Naloxegol

651,798 NA 4,2 6-11 2 h 7.42 8.65 203.0
Naldemedine

570,6 29 93-94 11 45 min 0.34 0.94 0.43

Methylnaltrexone bromide has poor oral bioavailability, and for that reason, every other day it is administered subcutaneously. About half of the dose is excreted in the urine and somewhat less in feces with 85% eliminated unchanged.[24]

Alvimopan has considerable low bioavailability (6%) due to its high binding affinity and low dissociation rate. Essentially, alvimopan is mediated by biliary secretion with an average plasma clearance of 400 ml/min. Metabolism of alvimopan is via intestinal flora resulting in hydrolysis of alvimopan to the active amide metabolite (ADL 08-0011). However, the metabolite is considered clinically irrelevant due to its low binding affinity.[25]

When naloxegol is given with a fatty meal, absorption increases. Clearance is mostly via hepatic metabolism (P450-CYP3A) with unknown actions of the metabolites. Naloxegol has small fragments eliminated by renal excretion.[30]

Naldemedine metabolites mainly via CYP3A to nor-naldemedine, it also metabolites via UDP-glucuronosyltransferase 1A3 to naldemedine 3-G, but in a lesser extent. Those metabolites are both opioid receptor antagonists but are less potent than the parent compound.[33]

PAMORAs in development

[edit]
Structure of axelopran

Axelopran is an oral PAMORA which is under development by Theravane Biopharma. It has completed phase II in clinical trials in more than 400 patients with OIC. Axelopran has a different chemical structure from other PAMORAs but with a similar mechanism of action. It acts as an antagonist for MOR, KOR and DOR, but with higher affinity for MOR and KOR than for DOR. Like other PAMORAs, the main goal is the treatment of OIC.[34] Axelopran is also being investigated in fixed-dose combination (FDC) with oxycodone. It is done by using spray coating technology to create an FDC of axelopran and controlled-release oxycodone.[35]

There is a demand for optimization of the receptor selectivity and affinity accompanied by an exploration of candidate compounds regarding their route of administration. These are the main objectives and future strategies for drug discovery and the development of PAMORAs. Predominantly, the MORs exhibit functionally selective agonism. Therefore, future possible candidate compounds that target OIC are PAMORAs with optimized selectivity and affinity.[27]

References

[edit]
  1. ^ Floettmann, Eike; Bui, Khanh; Sostek, Mark; Payza, Kemal; Eldon, Michael (May 2017). "Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation". The Journal of Pharmacology and Experimental Therapeutics. 361 (2): 280–291. doi:10.1124/jpet.116.239061. PMC 5399635. PMID 28336575.
  2. ^ Sizar, Omeed; Gupta, Mohit (2019). "Opioid Induced Constipation". National Center for Biotechnology information. StatPearls Publishing. PMID 29630236. Retrieved 4 June 2019.
  3. ^ Bui, Khanh; Zhou, Diansong; Xu, Hongmei; Floettmann, Eike; Al-Huniti, Nidal (June 2017). "Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist". Clinical Pharmacokinetics. 56 (6): 573–582. doi:10.1007/s40262-016-0479-z. PMID 28035588. S2CID 3458268.
  4. ^ "Drug developed at the University of Chicago wins FDA approval". University of Chicago News. 30 April 2008. Retrieved 30 April 2008.
  5. ^ a b c Carroll, F. Ivy; Dolle, Roland E. (2014). "The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of a pure opioid receptor antagonists". ChemMedChem. 9 (8): 1638–1654. doi:10.1002/cmdc.201402142. ISSN 1860-7187. PMC 5588862. PMID 24981721.
  6. ^ Zimmerman, Dennis M.; Nickander, Rodney; Horng, Jong S.; Wong, David T. (September 1978). "New structural concepts for narcotic antagonists defined in a 4-phenylpiperidine series". Nature. 275 (5678). Reprints and Permissions: 332–334. Bibcode:1978Natur.275..332Z. doi:10.1038/275332a0. PMID 692714. S2CID 4149532.
  7. ^ "Drug Approval Package: Entereg (Alvinopan) Capsules 21775". www.accessdata.fda.gov. FDA. Retrieved 18 July 2008.
  8. ^ Crockett, Seth D.; Greer, Katarina B.; Heidelbaugh, Joel J.; Falck-Ytter, Yngve; Hanson, Brian J.; Sultan, Shahnaz (January 2019). "American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation". Gastroenterology. 156 (1): 218–226. doi:10.1053/j.gastro.2018.07.016. PMID 30340754.
  9. ^ "Drug Approval Package: MOVANTIC (naloxegol) Tablets". www.accessdata.fda.gov. FDA.
  10. ^ "Symproic (naldemedine) Tablets". www.accessdata.fda.gov. FDA. Retrieved 4 May 2017.
  11. ^ Streicher, John M.; Bilsky, Edward J. (2017-09-25). "Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications". Journal of Pharmacy Practice. 31 (6): 658–669. doi:10.1177/0897190017732263. ISSN 0897-1900. PMC 6291905. PMID 28946783.
  12. ^ Brock, Christina; Olesen, Søren Schou; Olesen, Anne Estrup; Frøkjaer, Jens Brøndum; Andresen, Trine; Drewes, Asbjørn Mohr (2012-10-01). "Opioid-Induced Bowel Dysfunction". Drugs. 72 (14): 1847–1865. doi:10.2165/11634970-000000000-00000. ISSN 1179-1950. PMID 22950533. S2CID 173168.
  13. ^ a b Thomas, Jay (2008). "Opioid-induced bowel dysfunction". Journal of Pain and Symptom Management. 35 (1): 103–113. doi:10.1016/j.jpainsymman.2007.01.017. ISSN 0885-3924. PMID 17981003.
  14. ^ Ghelardini, Carla; Di Cesare Mannelli, Lorenzo; Bianchi, Enrica (2015). "The pharmacological basis of opioids". Clinical Cases in Mineral and Bone Metabolism. 12 (3): 219–221. doi:10.11138/ccmbm/2015.12.3.219. ISSN 1724-8914. PMC 4708964. PMID 26811699.
  15. ^ Torres, Daniele; Parrinello, Gaspare; Trapanese, Caterina; Licata, Giuseppe (2017). "Sudden severe abdominal pain after a single low dose of paracetamol/codein in a cholecystectomized patient: learning from a case report". American Journal of Therapeutics. 17 (4): e133–134. doi:10.1097/MJT.0b013e3181baf253. ISSN 1536-3686. PMID 19829093.
  16. ^ Brock, Christina; Olesen, Søren Schou; Olesen, Anne Estrup; Frøkjaer, Jens Brøndum; Andresen, Trine; Drewes, Asbjørn Mohr (2012-10-01). "Opioid-induced bowel dysfunction: pathophysiology and management". Drugs. 72 (14): 1847–1865. doi:10.2165/11634970-000000000-00000. ISSN 1179-1950. PMID 22950533. S2CID 173168.
  17. ^ a b Kaserer, Teresa; Lantero, Aquilino; Schmidhammer, Helmut; Spetea, Mariana; Schuster, Daniela (18 February 2016). "μ Opioid receptor: novel antagonists and structural modeling". Scientific Reports. 6: 21548. Bibcode:2016NatSR...621548K. doi:10.1038/srep21548. ISSN 2045-2322. PMC 4757823. PMID 26888328.
  18. ^ DeRuiter, Jack (2000). Principles of Drug Action (PDF). Auburn Education.
  19. ^ Haddou, Tanila Ben; Béni, Szabolcs; Hosztafi, Sándor; Malfacini, Davide; Calo, Girolamo; Schmidhammer, Helmut; Spetea, Mariana (11 June 2014). "Pharmacological Investigations of N-Substituent Variation in Morphine and Oxymorphone: Opioid Receptor Binding, Signaling and Antinociceptive Activity". PLOS ONE. 9 (6): e99231. Bibcode:2014PLoSO...999231B. doi:10.1371/journal.pone.0099231. ISSN 1932-6203. PMC 4053365. PMID 24919067.
  20. ^ Truong, Phong M.; Hassan, Sergio A.; Lee, Yong-Sok; Kopajtic, Theresa A.; Katz, Jonathan L.; Chadderdon, Aaron M.; Traynor, John R.; Deschamps, Jeffrey R.; Jacobson, Arthur E.; Rice, Kenner C. (15 April 2017). "Modulation of Opioid Receptor Affinity and Efficacy via N-Substitution of 9β-Hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and Computer Simulation Study". Bioorganic & Medicinal Chemistry. 25 (8): 2406–2422. doi:10.1016/j.bmc.2017.02.064. ISSN 0968-0896. PMC 5407189. PMID 28314512.
  21. ^ Kawamura, N.; Kataoka, T.; Imai, E.; Iwamura, T.; Hori, M.; Niwa, M.; Nozaki, M.; Fujimura, H. (1 January 1981). "Antagonist-Agonist Activity of Some N-Substituted Benzomorphans". Advances in Endogenous and Exogenous Opioids. Elsevier: 411–413. doi:10.1016/B978-0-444-80402-0.50138-8. ISBN 9780444804020.
  22. ^ a b Manglik, Aashish; Kruse, Andrew C.; Kobilka, Tong Sun; Thian, Foon Sun; Mathiesen, Jesper M.; Sunahara, Roger K.; Pardo, Leonardo; Weis, William I.; Kobilka, Brian K.; Granier, Sébastien (May 2012). "Crystal structure of the µ-opioid receptor bound to a morphinan antagonist". Nature. 485 (7398): 321–326. Bibcode:2012Natur.485..321M. doi:10.1038/nature10954. ISSN 1476-4687. PMC 3523197. PMID 22437502.
  23. ^ a b "Methylnaltrexone bromide". pubchem.ncbi.nlm.nih.gov.
  24. ^ a b R. William, Hipkin; Dolle, Roland E. (2010). "Chapter 9 - Opioid Receptor Antagonists for Gastrointestinal Dysfunction". Annual Reports in Medicinal Chemistry. 45: 142–155. doi:10.1016/S0065-7743(10)45009-5. ISBN 9780123809025.
  25. ^ a b Zabirowicz, Eric S.; Gan, Tong J. (2019). 34 - Pharmacology of Postoperative Nausea and Vomiting. Elsevier. pp. 671–692. doi:10.1016/B978-0-323-48110-6.00034-X. ISBN 9780323481106. S2CID 81387334.
  26. ^ a b "Naloxegol". pubchem.ncbi.nlm.nih.gov.
  27. ^ a b Streicher, John M.; Bilsky, Edward J. (December 2018). "Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications". Journal of Pharmacy Practice. 31 (6): 658–669. doi:10.1177/0897190017732263. ISSN 0897-1900. PMC 6291905. PMID 28946783.
  28. ^ Hu, Kenneth; Bridgeman, Mary Barna (October 2018). "Naldemedine (Symproic) for the Treatment Of Opioid-Induced Constipation". Pharmacy and Therapeutics. 43 (10): 601–627. ISSN 1052-1372. PMC 6152697. PMID 30271103.
  29. ^ Inagaki, Masanao; Kume, Masaharu; Tamura, Yoshinori; Hara, Shinichiro; Goto, Yoshihisa; Haga, Nobuhiro; Hasegawa, Tsuyoshi; Nakamura, Takashi; Koike, Katsumi; Oonishi, Shuuichi; Kanemasa, Toshiyuki; Kai, Hiroyuki (1 January 2019). "Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects". Bioorganic & Medicinal Chemistry Letters. 29 (1): 73–77. doi:10.1016/j.bmcl.2018.11.007. ISSN 0960-894X. PMID 30446313.
  30. ^ a b Turan, Alparslan; Saasouh, Wael; Hovsepyan, Karen; You, Jing. "Ancillary Effects of Oral Naloxegol (Movantik)" (PDF). Clinicaltrials.gov.
  31. ^ "Methylnaltrexone bromide". pubchem.ncbi.nlm.nih.gov.
  32. ^ Kanemasa, Toshiyuki; Koike, Katsumi; Arai, Tohko; Ono, Hiroko; Horita, Narumi; Chiba, Hiroki; Nakamura, Atsushi; Morioka, Yasuhide; Kihara, Tsuyoshi; Hasegawa, Minoru (1 May 2019). "Pharmacologic effects of naldemedine, a peripherally acting μ‐opioid receptor antagonist, in in vitro and in vivo models of opioid‐induced constipation". Neurogastroenterology & Motility. 31 (5): e13563. doi:10.1111/nmo.13563. ISSN 1365-2982. PMC 6850587. PMID 30821019.
  33. ^ Markham, Anthony (May 2017). "Naldemedine: First Global Approval". Drugs. 77 (8): 923–927. doi:10.1007/s40265-017-0750-0. PMID 28466424. S2CID 19271743.
  34. ^ Pannemans, Jasper; Vanuytsel, Tim; Tack, Jan (October 2018). "New developments in the treatment of opioid-induced gastrointestinal symptoms". United European Gastroenterology Journal. 6 (8): 1126–1135. doi:10.1177/2050640618796748. PMC 6169055. PMID 30288274.
  35. ^ "Theravance Biopharma: Programs | Gastrointestinal Motility Dysfunction". SITE.


Retrieved from "http://en.wiki.x.io/w/index.php?title=Peripherally_acting_μ-opioid_receptor_antagonist&oldid=1245143388"